Log In
BCIQ
Print this Print this
 

Glufast, mitiglinide (Glinsuna) (KAD-1229)

  Manage Alerts
Collapse Summary General Information
Company Kissei Pharmaceutical Co. Ltd.
DescriptionInsulin secretagogue
Molecular Target ATP-dependent potassium channel (KATP)
Mechanism of ActionATP-dependent potassium channel (KATP) blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerEisai Co. Ltd.;
Orient Europharma Co. Ltd.;
Takeda Pharmaceutical Co. Ltd.;
USV Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/25/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today